仲圣医事通
Published by:
河南仲圣科技有限公司
Description
仲圣医事通是由仲圣平台投资开发的多商线上平台，致力于为广大基层门诊、药房、综合医疗服务机构提供中药饮片、中医器械等线上交易的数字化综合服务采购平台。
平台努力以安全高效的方式将医药健康产品及服务带给下游，使用户都能以公平且透明的价格轻松获得大量、全面且有品质保证的药品。以构建更安全更高效的医药产业交易与服务平台为使命，驱动医疗健康生态系统整体效率的提升。
平台努力以安全高效的方式将医药健康产品及服务带给下游，使用户都能以公平且透明的价格轻松获得大量、全面且有品质保证的药品。以构建更安全更高效的医药产业交易与服务平台为使命，驱动医疗健康生态系统整体效率的提升。
Screenshots
仲圣医事通 FAQ
-
Is 仲圣医事通 free?
Yes, 仲圣医事通 is completely free and it doesn't have any in-app purchases or subscriptions.
-
Is 仲圣医事通 legit?
Not enough reviews to make a reliable assessment. The app needs more user feedback.
Thanks for the vote -
How much does 仲圣医事通 cost?
仲圣医事通 is free.
-
What is 仲圣医事通 revenue?
To get estimated revenue of 仲圣医事通 app and other AppStore insights you can sign up to AppTail Mobile Analytics Platform.
User Rating
App is not rated in Ukraine yet.
Ratings History
仲圣医事通 Reviews
Store Rankings
Ranking History
App Ranking History not available yet
Category Rankings
App is not ranked yet
仲圣医事通 Installs
Last 30 days
仲圣医事通 Revenue
Last 30 days仲圣医事通 Revenue and Downloads
Gain valuable insights into 仲圣医事通 performance with our analytics.
Sign up now to access downloads, revenue, and more.
Sign up now to access downloads, revenue, and more.
App Info
- Category
- Shopping
- Publisher
-
河南仲圣科技有限公司
- Languages
- English, Chinese
- Recent release
- 1.0.25 (1 week ago )
- Released on
- May 10, 2024 (8 months ago )
- Also available in
- China, Singapore, South Korea, Kuwait, Nigeria, Norway, Pakistan, Poland, Portugal, Russia, Saudi Arabia, Israel, Thailand, Türkiye, Taiwan, Ukraine, United States, Vietnam, South Africa, Denmark, Australia, Azerbaijan, Belgium, Brazil, Switzerland, Chile, Czechia, Germany, India, Algeria, Ecuador, Egypt, Greece, Hong Kong SAR China, Hungary, Ireland, Argentina
- Last Updated
- 1 week ago
This page includes copyrighted content from third parties, shared solely for commentary and research in accordance with fair use under applicable copyright laws. All trademarks, including product, service, and company names or logos, remain the property of their respective owners. Their use here falls under nominative fair use as outlined by trademark laws and does not suggest any affiliation with or endorsement by the trademark holders.